Sign in
Taking people in United StatesNo phase

Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation

Key facts

Who runs it
Francisco Gonzalez-Lima, PhD
Where
Austin, United StatesSee the site
Trial code
Status
Recruiting
People taking part
500 people, planned
Started
9 Feb 2022
Expected to end
1 Feb 2027
Type of study
Interventional, 4 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Transcranial photobiomodulation
  • Sham transcranial photobiomodulation
Record updated
22 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • 18 years of age or older

Who cannot take part

  • None

Where in United States

  • The University of Texas at AustinAustin, United StatesContact: Francisco Gonzalez-Lima, PhDTaking people

About the trial

What the trial wants to find out

Inattentiveness and impulsivity in healthy adults and individuals with attention deficit hyperactivity disorder (ADHD) diminish these individuals' quality of life. Cortical hypometabolism has been hypothesized to contribute to inattentiveness in ADHD. Transcranial photobiomodulation (tPBM) is a safe and non-invasive modality for activation of the prefrontal cortex. tPBM in healthy adults has been shown to augment brain oxygenation, cognition, and mood. The cognition-enhancing effect of tPBM on sustained attention in adults with ADHD remains unstudied. The investigators will evaluate whether tPBM administration to adults with and without ADHD can improve their attention. Each participant will be screened for eighteen criteria based on the Diagnostic and Statistical Manual (DSM-IV, text revised), using the validated instrument Adult ADHD Self-Report Scale (ASRS-v1.1). Blinded participants will be randomized into (I) Active-tPBM or (II) Sham-tPBM groups. After undergoing an 8-minute administration of Sham or 1064 nm tPBM to the lateral and medial right prefrontal cortex, each participant will complete a 14-minute, computer-based Conner's continuous performance task-3 (CPT-3). The investigators will examine whether adults with and without ADHD who receive Active-tPBM improve in measures of inattention, impulsivity, sustained attention, or vigilance compared to the Sham-tPBM group. Cognitive assessments of attention like the CPT-3 may evaluate the efficacy of tPBM to increase cortical metabolism in healthy adults and individuals with conditions like ADHD. The investigators anticipate their investigation will be a starting point for more sophisticated studies that focus on the implications of tPBM on cognition.

The 4 groups in the trial

  • Sham-tPBM, non-ADHDSham treatment, for comparison

    Participants with no medical diagnosis of ADHD will be exposed to the same conditions as treated participants, with the exception that the infrared light will be turned off (sham condition).

    Treatment: Sham transcranial photobiomodulation

  • Sham-tPBM, ADHDSham treatment, for comparison

    Participants with a medical diagnosis of ADHD will be exposed to the same conditions as treated participants, with the exception that the infrared light will be turned off (sham condition).

    Treatment: Sham transcranial photobiomodulation

  • tPBM, non-ADHDTreatment being tested

    Participants with no medical diagnosis of ADHD will be exposed to the same conditions as sham participants, with the exception that the infrared light will be turned on (treated condition).

    Treatment: Transcranial photobiomodulation

  • tPBM, ADHDTreatment being tested

    Participants with a medical diagnosis of ADHD will be exposed to the same conditions as sham participants, with the exception that the infrared light will be turned on (treated condition).

    Treatment: Transcranial photobiomodulation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
22 June 2026